stock
EWTX · Edgewise Therapeutics, Inc.
What Edgewise Therapeutics, Inc. reports to the SEC, read from its filings.
Open in the appPrice
The live EWTX price and today's change.
Sign in to see thisChart
Thirty days of daily bars, with signal levels drawn on them.
Sign in to see thisSignals
The latest signal group Nakagai's scanner recorded on EWTX.
Sign in to see thisOptions positioning
Gamma exposure levels from the options market.
Sign in to see thisTechnicals
Trend, momentum and volatility gauges per timeframe.
Sign in to see thisWhat it is
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Filer (SEC EDGAR)
- EDGAR filing index
- Shares outstanding
- 108,604,129 as of 2026-07-31 (XBRL frame CY2026Q2I)
Key stats
Valuation
- P/E
- Locked
- P/S
- Locked
- P/B
- Locked
- Enterprise value
- Locked
- EV/EBIT
- Locked
- FCF yield
- Locked
Margins
- Gross
- —
- Operating
- —
- Net
- —
Returns
- ROE
- -6.6%
- ROA
- -6.2%
Health
- Current ratio
- 16.2x
- Debt/equity
- —
Deep value
- NCAV
- $439.91M
- NCAV per share
- $4.05
- Price/NCAV
- Locked
- NNWC
- $40.71M
- NNWC per share
- $0.37
- Price/NNWC
- Locked
Valuation and the price multiples are built on the live price. Trailing twelve months to 2026-06-30; balance sheet at 2026-06-30.
Sign in to see thisDebt is long-term debt and its current portion. Commercial paper and short-term borrowings are not counted.
Results
| Period end | Revenue (not reported by this company) | Gross profit (not reported by this company) | Operating income | Net income | Filing |
|---|---|---|---|---|---|
| 2026-06-30 | —Revenue: unreported by this company. | —Gross profit: unreported by this company. | -$61.94M | -$57.33M | 10-Q filed 2026-08-06 |
| 2026-03-31 | —Revenue: unreported by this company. | —Gross profit: unreported by this company. | -$54.12M | -$49.01M | 10-Q filed 2026-08-06 Assembled from more than one filing; the filing above is only the newest of them. |
| 2025-12-31 | —Revenue: unreported by this company. | —Gross profit: unreported by this company. | -$55.98M | $117.41M | DEF 14A filed 2026-04-23 Derived: the full year minus the first three quarters, not a figure this filer reported as a quarter. Assembled from more than one filing; the filing above is only the newest of them. |
| 2025-09-30 | —Revenue: unreported by this company. | —Gross profit: unreported by this company. | -$46.86M | -$40.67M | 10-Q filed 2025-11-06 |
| 2025-06-30 | —Revenue: unreported by this company. | —Gross profit: unreported by this company. | -$42.61M | -$36.12M | 10-Q filed 2026-08-06 |
| 2025-03-31 | —Revenue: unreported by this company. | —Gross profit: unreported by this company. | -$45.96M | -$40.80M | 10-Q filed 2026-08-06 Assembled from more than one filing; the filing above is only the newest of them. |
| 2024-12-31 | —Revenue: unreported by this company. | —Gross profit: unreported by this company. | -$45.54M | $94.02M | DEF 14A filed 2026-04-23 Derived: the full year minus the first three quarters, not a figure this filer reported as a quarter. Assembled from more than one filing; the filing above is only the newest of them. |
| 2024-09-30 | —Revenue: unreported by this company. | —Gross profit: unreported by this company. | -$40.43M | -$34.13M | 10-Q filed 2025-11-06 |
- Assets
- $479.69M
- Equity
- $448.08M
Balance as of 2026-06-30.
Ten years
| Fiscal year end | Revenue | Operating income | Net income | Free cash flow |
|---|---|---|---|---|
| 2025-12-31 | — | -$191.41M | -$167,795 | -$144.07M |
| 2024-12-31 | — | -$158.83M | -$133,813 | -$110.34M |
| 2023-12-31 | — | -$114.36M | -$100,163 | -$97.69M |
| 2022-12-31 | — | -$71.66M | -$67.64M | -$58.18M |
| 2021-12-31 | — | -$43.22M | -$42.81M | -$34.17M |
| 2020-12-31 | — | -$17.19M | -$17.12M | -$14.84M |
Company filings
events
5% owners ()
RA Capital Management, L.P.
Stake update
Paradigm BioCapital Advisors LP
Stake update
Baker Bros. Advisors LP
Stake update
FMR LLC
Passive stake
JANUS HENDERSON GROUP PLC
Passive stake
Insiders, politicians and funds
Insider trades, last 90 days
Donovan Joanne M.
CMO
Sale$412,703Aug 14, 4:54 PM ET
Russell Alan J
Chief Scientific Officer, Director
Sale$258,042Aug 14, 4:53 PM ET
MOORE JOHN R
General Counsel
Sale$219,823Aug 14, 4:53 PM ET
Derakhshan Behrad
Chief Business Officer
Sale$223,424Aug 14, 4:53 PM ET
KOCH KEVIN
President and CEO, Director
Sale$785,042Aug 14, 4:52 PM ET
Politician trades, last 90 days
No politician trades filed in the last 90 days.
News
Stories that named EWTX, and the market events around them.
Sign in to see thisBoard
Recent signals
Signals open up here once a member has posted about EWTX.
Signals are informational.
Posts · 0
No posts yet.
nakagai
Signals on EWTX come from a rule, not a model.
Nakagai’s scanner records a signal the moment a strategy’s rule matches on the bars. Members read those signals on their own desk, where an agent journals the tape and briefs them in plain English.
Members post on the EWTX board